title: Review of ranibizumab trials for neovascular age-related macular degeneration.
abstract: Ranibizumab, a recombinant, humanized, monoclonal antibody antigen-binding fragment that neutralizes all VEGF-A isoforms, is the first US FDA-approved therapy for neovascular age-related macular degeneration (AMD) to result in improvement in visual acuity. The benefit of intravitreal ranibizumab applies to all angiographic subtypes of neovascular AMD and across all lesion sizes. The two original phase III studies (ANCHOR and MARINA) demonstrated sustained visual acuity (VA) gains over a two-year monthly dosing schedule. Following these trials, several studies looked at ways to decrease the treatment burden while maintaining similar visual gains. These trials included PIER, PrONTO, EXCITE, SUSTAIN, HORIZON, and CATT. Visual acuity data shows that monthly dosing of ranibizumab produces superior vision outcomes compared to a less-frequent, fixed-dosing schedule. Intravitreal ranibizumab is well tolerated and shown to have a very low rate of adverse ocular or systemic side-effects.
authors: University of Chicago, Department of Surgery, Section of Ophthalmology and Visual Science, Chicago, IL, USA.
authors: Ravi D
authors: RD
authors: Patel
authors: Rominder S
authors: RS
authors: Momi
authors: Seenu M
authors: SM
authors: Hariprasad
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D006801:Humans; D000069579:Ranibizumab; D014792:Visual Acuity / Q000502:physiology; D057135:Wet Macular Degeneration / Q000188:drug therapy*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab